Nanhua Bio (000504.SZ): Cell therapy-related technologies and products are still in the R&D stage.

Zhito Finance APP News: Nanhua Bio (000504.SZ) issued a stock trading risk warning announcement stating that the company's current main businesses are biomedicine and energy conservation and environmental protection. Among them, the biomedicine segment mainly provides customers with testing and storage services for biological resources such as stem cells and immune cells, and also cooperates with multiple clinical research institutions to provide them with cell preparation, testing, and other services that meet clinical research requirements. The company's cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage; the energy conservation and environmental protection segment is mainly engaged in lithium carbonate business, scrap steel renewable resources, and supporting processing and sales businesses.